TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Adherence to prescribed exercise program
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: proportion of days abstinent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: proportion of days of heavy drinking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: time to the return of heavy drinking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Variations in VO2 max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Language Content Production for Treated Stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Production of Language Content for Untreated Sets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Opioid and/or BZD use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Great Saphenous Vein Occlusion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Participants With Total Cardiovascular Disease (CVD) Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Invasive Cancer Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of subjects of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects With Significant Abnormal Physical Examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects With Significant Abnormal Electrocardiography (ECG) Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence Rate of Participants Achieving Loss of Response (LOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postexercise central blood pressure response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Daily OFF Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-phase insulin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rate of characteristics indicative of future HALT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking related performance fatigability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative volume of wound drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fecal calprotectin reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Eye-tracking pupil position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of change on the Yale-Brown Obsessive Compulsive Disorder Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Patients Who Meet Criteria for Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported degree of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Neutrophil Count in Induced Sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pharmacokinetic profile of eravacycline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of emergence delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Female Sexual Function Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: International Erectile Function Form
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of Residual Neuromuscular Blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in PPi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in NPP1-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in TNAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity of cardiac MRI for detecting heart transplant rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Specificity of cardiac MRI for detecting heart transplant rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effective rate of abdominal pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Revision surgeries
Endpoint domain: Adverse events/effects
Primary endpoint: Regional (neck) nodal control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: New acute myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: New unstable angina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cosmetic Outcome of Scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Disability: Oswestry Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Perceived Stress Scale-10 (PSS-10)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Median effect dose of intranasal dexmedetomidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wrinkle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Abnormal laboratory findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cerebral performance Category (CPC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CTC/DTC numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of patients receiving HCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Levels of insight or awareness of violence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Health Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of virulence genes in UPEC strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of intracranial hemorrhage requiring hospital admission
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Detrusor Leak Point Pressure (LPP) < 40 cm H2O
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cmax eptinezumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-t) eptinezumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-inf) eptinezumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic Clearance of eptinezumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of arterial access related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Completion of diagnostic ultrasound exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of intestinal flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Benznidazole concentration in breastmilk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Benznidazole concentration in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Level of bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the frequency of monthly migraine episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinically relevant postoperative pancreatic fistula (CR-POPF)
Endpoint domain: Adverse events/effects
Primary endpoint: Outcomes of patients with persistent Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma Pazopanib Area Under the Concentration-time Curve (AUC[0-24])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Maximum Observed Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum Pain Intensity Difference - Baseline to 24 Hours (SPID24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Achieving Overall Response Rate (Partial Response [PR] Plus Complete Response [CR])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum intraocular pressure (IOP) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sublingual microvascular flow index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Difference Between Arm and Leg Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severity rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Residual Cancer Burden (RCB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Postoperative non-cardiovascular complications
Endpoint domain: Adverse events/effects
Primary endpoint: Loss in best corrected visual acuity (BCVA) of greater than or equal to 15 letters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distant Metastasis Free Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients who fail to complete therapy
Endpoint domain: Life impact
Endpoint subdomain: Need for further intervention
Primary endpoint: Frequency of clinical and laboratory adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Brown adipose tissue activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: One-year recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Who Achieved MMPS Grade ≤ 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With at Least One TEAE
Endpoint domain: Adverse events/effects
Primary endpoint: Pregnancy Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Rate of patients progression free at 3 months
Endpoint domain: Mortality/survival
Primary endpoint: CDR Power of Attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroop Test Interference T-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adult Attention Deficit Hyperactivity Disorder (ADHD) Self-Report Scale Summary Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neonate respiratory distress syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fraction of Middle Ear Pressure Equilibrated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MPFC-amygdala functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients with Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Lymph node areas colored by the diffusion of the blue patent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Cumulative endoscopic healing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Maintaining SVR at the Last Available Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Percentage of Participants With Change in Sequence of HCV NS3/4A Region Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Change in Sequence of HCV NS3/4A Region Over Time (With Q80K at Baseline)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Change in Sequence of HCV NS3/4A Region Over Time (Without Q80K at Baseline)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain assessment using visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First-tie success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Electroretinogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of ESBL Klebsiella pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Preoperative Fasting Blood Sugar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: head movement during writing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central blood pressure changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ambulatory Pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Ambulatory Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Impact of Event-Revised Intrusion Subscale (IES-R)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Functional Assessment of Cancer Therapy--General Version
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Functional Assessment of Chronic Illness-Spiritual Well-being Scale (FACIT-SP)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the plasma concentration vs time curve (AUC0-120)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the blood concentration vs time curve (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Amount of Opioids at 48 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients receiving chemotherapy in the last 30 days of life
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from baseline on the Aberrant Behavior Checklist-Community measure (irritability and stereotypy subscales)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stem Survivorship (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Carotid artery Intima-media thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Count of Participants Experiencing One or More Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease radicular pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COPD hospitalization rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of Participants Achieving SLE Responder Index Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of tubular dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Respiratory Events Requiring Intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Breathing muscle oxygen cost
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Respiratory muscle blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of Words Correctly Recognised
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total Number of Correct Sequences Recalled
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Combined Z Score of Delayed Words Recalled, Words Recognised, and Pictures Recognised
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pain scorings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 2 or higher clinical and laboratory adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Correlation with histological findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Correlation coefficient between biochemical and histological composition of the thrombus and fibrinolysis sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Duration of fever subsided to normal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of growth over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent of women requesting treatment for heavy menstrual blood loss
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pharmacokinetic Profile of Darbe After the First Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic Profile of Darbe After the Second Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Synaptamide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in forefoot supination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in forefoot adduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Severity of MDD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Mania symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histogram metrics for cervical cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in hemoglobin over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in cognitive function measured by MMSE
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in cognitive function measured by Cornell Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: change in c reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in super oxide dismutase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in probing depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in clinical attachment loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transition Readiness Assessment Questionnaire (TRAQ) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With the Composite Primary Outcome
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Who Had a Fetus or Neonate With CMV Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants Who Had a Neonatal Death Without CMV Infection
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With a Fetal or Neonatal Death With Proven CMV Infection
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Fetal Death Without Proven CMV Infection
Endpoint domain: Mortality/survival
Primary endpoint: Duration of Disease Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Actigraphy indices
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Sleep Diary variables
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Insomnia Severity Index (ISI) scores
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Pittsburgh Sleep Quality Index (PSQI) scores
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Self-reported complaints
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in ocular structure parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of Lesions Detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of SVCF
Endpoint domain: Mortality/survival
Primary endpoint: Preeclampsia prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RPDII)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of Referral Warranted ROP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Frequency of implant sites with biological complications
Endpoint domain: Adverse events/effects